肾康饮对早期糖尿病肾病患者MMP-9及TIMP-1水平的影响

刘文清 胡连海 张继东

肾康饮对早期糖尿病肾病患者MMP-9及TIMP-1水平的影响

刘文清胡连海张继东

[1]中国人民解放军第八十八医院, 山东泰安271000 [2]山东大学齐鲁医院, 山东济南250012

计量
- 文章访问数: 1328
- HTML全文浏览量: 4
- PDF下载量: 0
- 被引次数: 0
出版历程
- 收稿日期: 2006-05-10
- 刊出日期: 2006-09-10

Effect of Shenkangyin on MMP-9 and TIMP-1 Levels of Patients with Early Diabetic Nephropathy

LIU Wen-qing, HU Lian-hai, ZHANG Ji-dong

摘要

摘要: 目的观察肾康饮对早期糖尿病肾病患者基质金属蛋白酶．9（MMP-9）及基质金属蛋白酶组织抑制因子-1（TIMP-1）水平的影响，以了解其对早期糖尿病肾病的作用机理。方法60例早期糖尿病肾病患者随机分为治疗组和对照组，治疗组在常规服用卡托普利的基础上加用肾康饮，对照组只用卡托普利治疗，疗程为4周，治疗前后检测空腹血糖（rv6）、尿微量白蛋白（UMA）、MMP-9、TIMP-1的水平。结果2组治疗后UMA、TIMP-1下降，MMP-9水平升高，较治疗前均有显著差异（P〈0.05）；试验组UMA、TIMP-1水平下降，MMP-9水平升高较对照组更为显著（P〈0．05，P〈0．01）。试验组FPG水平下降，较治疗前有显著差异（P〈0.05）。结论肾康饮升高MMP-9、降低TIMP-1效果显著，通过调节MMP-9／TIMP-1的平衡，抑制肾小球基底膜增厚、细胞外基质（ECM）增殖而发挥治疗作用。

Abstract: OBJECTIVE To observe the effect of Shenkangyin on MMP-9 and TIMP-1 levels of patients with early diabetic nephropathy,so as to understand its mechanism in treating early diabetic nephropathy.METHOD 60 patients were randomly divided into a treatment group and a control group,the former taking captopril and Shenkangyin and the latter taking only captopril for 4 week.RESULT After the treatment,UMA and TIMP-1 levels decreased and MMP-9 level increased in the treatment group,with marked difference as compared with the levels before the treatment(P<0.05).In the experimental group,the changes were even more obvious(P<0.05,P<0.01).In the experimental group,FPG level decreased,with marked difference as compared with the levels before the treatment(P<0.05).CONCLUSION Shenkangyin can markedly increase MMP-9 level and decrease TIMP-1 level,owing its effect of regulating MMP-9/TIMP-1 balance and inhibiting the thickening of the glomerular basement membrane and the hyperplasia of extracellular matrix.

HTML全文

参考文献(7)

[1]	Bloomgarden ZT.International Diabetes Federation Meeting.diabetes,its prewalence,causes and treatment[J].Diabetes Care,1998,2(5):860.
[2]	Mogensen CE.Early golmerular hyperfitration in insulindapendent diabeties and late nephropathy[J].Scand J Clin Lab Invest,1986,46:201.
[3]	王海燕.肾脏病学.第2版[M].北京:人民卫生出版社,1996.956.
[4]	陈佑邦.中医病症诊断疗效标准[M].南京:南京大学出版社,1991.48.
[5]	Schnaper HW.Balance between matrix synthesis and degradation:adeterminant of glomerulosclerosis[J].Pediatr Nephrol,1995,2:104.
[6]	Benyon RG,Arthur MJ.Extracellularmatrix degradation and the role of hepatic stellate cells[J].Semin Liver Dis,2001,21:373.
[7]	Schaefer L,Han X,August C,et al.Differential regulation of glomerular gelatinase B(MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in obese zucker rate[J].Diabetologia,1997,40:1035.